"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
Sotradecol® (sodium tetradecyl) (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous Injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.
The intravenous LDĄ of sodium tetradecyl sulfate in mice was reported to be 90 ± 5 mg/kg.
In the rat, the acute intravenous LDĄ of sodium tetradecyl sulfate was estimated to be between 72 mg/kg and 108 mg/kg.
Purified sodium tetradecyl sulfate was found to have an LDĄ of 2 g/kg when administered orally by stomach tube as a 25% aqueous solution to rats. In rats given 0.15 g/kg in drinking water for 30 days, no appreciable toxicity was seen, although some growth inhibition was discernible.
Last reviewed on RxList: 7/16/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Sotradecol Information
Report Problems to the Food and Drug Administration
Find out what women really need.